| アブストラクト | Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved June 2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration adverse event reporting system (July 2014 through December 2016), we observed significantly increased risks of thrombocytopenia of similar magnitudes with both antibiotics: linezolid reporting odds ratio [ROR], 37.9 (95% confidence interval [CI], 20.78 to 69.17); tedizolid ROR, 34.0 (95% CI, 4.67 to 247.30). |
|---|
| 組織名 | University of Rhode Island, College of Pharmacy, Kingston, Rhode Island, USA.;University of Rhode Island, College of Pharmacy, Kingston, Rhode Island, USA;Aisling_Caffrey@uri.edu.;Veterans Affairs Medical Center, Infectious Diseases Research Program and Center;of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA.;Brown University, School of Public Health, Providence, Rhode Island, USA. |
|---|
